These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 9374386

  • 21. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T.
    Cancer; 2001 Sep 15; 92(6):1577-90. PubMed ID: 11745237
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD.
    Clin Cancer Res; 2002 Mar 15; 8(3):670-8. PubMed ID: 11895894
    [Abstract] [Full Text] [Related]

  • 23. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Mar 15; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 24. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL.
    Clin Cancer Res; 1997 Nov 15; 3(11):1977-84. PubMed ID: 9815587
    [Abstract] [Full Text] [Related]

  • 25. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [Abstract] [Full Text] [Related]

  • 26. Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.
    Weinländer G, Kornek G, Raderer M, Hejna M, Tetzner C, Scheithauer W.
    J Cancer Res Clin Oncol; 1997 Dec 15; 123(8):452-5. PubMed ID: 9292709
    [Abstract] [Full Text] [Related]

  • 27. Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes.
    Urien S, Nguyen P, Bastian G, Lucas C, Tillement JP.
    Invest New Drugs; 1995 Dec 15; 13(1):37-41. PubMed ID: 7499106
    [Abstract] [Full Text] [Related]

  • 28. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
    Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ.
    Cancer; 2007 Mar 01; 109(5):924-32. PubMed ID: 17285598
    [Abstract] [Full Text] [Related]

  • 29. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG.
    J Natl Cancer Inst; 1992 Jun 17; 84(12):929-37. PubMed ID: 1629914
    [Abstract] [Full Text] [Related]

  • 30. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
    Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA.
    Clin Cancer Res; 2004 May 15; 10(10):3265-72. PubMed ID: 15161679
    [Abstract] [Full Text] [Related]

  • 31. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
    Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP.
    J Clin Oncol; 1995 Aug 15; 13(8):1958-65. PubMed ID: 7636536
    [Abstract] [Full Text] [Related]

  • 32. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
    Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ, Eeltink C, Vermorken JB, Pinedo HM.
    Clin Cancer Res; 1997 Nov 15; 3(11):2005-15. PubMed ID: 9815591
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS.
    Cancer Chemother Pharmacol; 2003 Apr 15; 51(4):297-305. PubMed ID: 12721757
    [Abstract] [Full Text] [Related]

  • 34. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.
    Clin Cancer Res; 1997 May 15; 3(5):755-60. PubMed ID: 9815746
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.
    Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, Aizawa T, Watanabe T, Uda Y, Tanigawara Y, Sasaki Y.
    Jpn J Cancer Res; 2001 Feb 15; 92(2):220-30. PubMed ID: 11223552
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of verapamil and S9788 on MDR-1 mRNA expression studied by in situ hybridization.
    Joly P, Lallemand A, Oum'Hamed Z, Trentesaux C, Idoine O, Desplaces A.
    Anticancer Res; 1996 Feb 15; 16(6B):3609-14. PubMed ID: 9042229
    [Abstract] [Full Text] [Related]

  • 39. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.
    Merlin JL, Marchal S, Ramacci C, Dieterlen A, Schultz G, Lucas C, Poullain MG, Berlion M.
    Cytometry; 1995 Aug 01; 20(4):315-23. PubMed ID: 7587719
    [Abstract] [Full Text] [Related]

  • 40. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
    Mickisch GH, Noordzij MA, vd Gaast A, Gebreamlack P, Köhrmann KU, Mogler-Drautz E, Kupper H, Schröder FH.
    J Cancer Res Clin Oncol; 1995 Aug 01; 121 Suppl 3():R11-6. PubMed ID: 8698736
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.